Giovanni Caforio, Bristol Myers Squibb CEO (Christopher Goodney/Bloomberg via Getty Images)

Bris­tol My­ers meets some di­ver­si­ty goals ear­ly, while miss­ing oth­ers

Bris­tol My­ers Squibb has met some of its big health eq­ui­ty goals ear­ly, while miss­ing two in­ter­nal goals fo­cused on di­ver­si­fy­ing its work­force. Now, the com­pa­ny says it’s set­ting the bar a lit­tle high­er.

Bris­tol My­ers an­nounced on Wednes­day that rough­ly 58% of its clin­i­cal tri­al sites are now lo­cat­ed in eth­ni­cal­ly di­verse ar­eas, sur­pass­ing its ini­tial goal of 25%. The news comes as the pan­dem­ic casts a harsh spot­light on the lack of di­ver­si­ty in clin­i­cal tri­als. Of the 53 drugs ap­proved in 2020, Black pa­tients rep­re­sent­ed just about 8% of tri­al par­tic­i­pants that reg­u­la­tors based their de­ci­sions on, and His­pan­ic pa­tients rep­re­sent­ed just over 12.6%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.